Circassia shares crumble as PhIII flop blights the sector once again
When Circassia Pharmaceuticals went public on the London Stock Exchange two years ago, raising a whopping $300 million, the British biotech community brimmed with enthusiasm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
